This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech-Stock Mailbag: Sangamo

Originally posted on at 6:59 a.m. EDT

This week's Biotech Mailbag kicks off with an email from David V., who asks:
Would you comment on Sangamo BioSciences' (SGMO - Get Report) recent downturn, which was spurred by Brean Murray Carret analyst Jonathan Aschoff saying that the midstage trial to treat diabetic neuropathy is expected to fail?

I first wrote about Sangamo last August because the company had an interesting story to tell, even if there were scant clinical data to back it up. Sangamo is engineering protein "switches," called zinc fingers, that can turn genes on or off. It's similar to the work being conducted with RNA interference, or RNAi, with one big difference: RNAi can only turn genes off, while zinc finger proteins have the ability to switch genes off and on.

Sangamo's lead pipeline drug, SB-509, is being developed as a way to turn on a gene that will regenerate nerves in patients with diabetic neuropathy.

The stock was at $10 when I penned that piece last August. It then ran all the way to $19 in November before retreating to around $9 in March. Another surge pushed the stock back above $13 recently, but then Brean Murray's Aschoff initiated coverage of the stock with a sell rating in late May, and the stock is now back under $9. (Biotech: a beta lover's dream.)

I've read Aschoff's notes and believe he raises some important questions and concerns about the clinical data presented on SB-509 to date.

The only data we have on the drug come from a phase Ib study in 24 mild-to-moderate diabetic neuropathy patients. Updated results were presented at this week's American Diabetes Association meeting. Sangamo reported a statistically significant clinical benefit favoring SB-509 on two measures of nerve health -- the neuropathy impairment score in the lower limbs (NIS-LL) and quantitative sensory testing, or QST.

Aschoff points out that SB-509 failed to show a statistically significant benefit on two other important tests of nerve health, most significantly the nerve conduction velocity (NVC) test, which measures a nerve's ability to conduct electrical impulses.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
CTIC $1.52 -1.94%
GILD $102.06 0.15%
MDVN $88.38 0.73%
PPHM $1.18 0.85%
SGMO $6.57 -0.90%


Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs